Compare Fiverr International Ltd (FVRR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Novo Nordisk A/S — how do they compare? Fiverr International Ltd trades at $8.75 (market cap $314.57M), while Novo Nordisk A/S trades at $46.2 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 660.7× Fiverr International Ltd's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals.
| FVRR | NVO | |
|---|---|---|
Market Cap | $314.57M | $207.85B |
Sector | Industrials | Health |
52-Week High | $26.67 | $63.98 |
52-Week Low | $8.75 | $35.29 |
Enterprise Value | $66.95M | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $8.71, down 4.18% over 24 hours, reflecting bearish technical signals and recent earnings misses. The stock shows attractive valuation multiples with a P/E of 10.8 and P/S of 0.77, while revenue grew to $430.91M in 2025. However, Q2 2026 results missed expectations, with revenue declining 10% year-over-year due to AI disruption pressures, as reported by MarketBeat on July 29, 2026.
The outlook remains cautious with significant AI-related headwinds compressing demand for freelance services. Near-term risks include execution challenges in a shifting competitive landscape, but the current low valuation may offer contrarian appeal if the company successfully adapts its strategy.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
